Puma Biotechnology Inc(PBYI): For the most recent quarter end, Puma Biotechnology Inc reported Annual Earnings of $-2.02. Based on the filings, last years Annual Earnings was, $-7.45. For the most recent quarter end, PBYI reported a surprise Earnings per Share of -1% . The consensus estimate for current quarter is $-2.02 and for the current fiscal year, the estimate is $-8.05. For the Next fiscal year, the estimate is $-7.33 based on the consensus.
Puma Biotechnology Inc has received $-2.02 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 2 Financial Advisor in the Stock Trading Firms. Among 2 Analysts, Bottom line EPS Estimate for the current quarter is $-2.04 while the top line estimate is $-2 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -6.32%. Puma Biotechnology Inc results fell short with a surprise EPS of -1% or $-0.02. The Actual EPS was $-2.02 compared to the Estimated EPS of $-2 during its most recent quarterly earnings.
Company has reported several Insider transactions to the SEC, on Jan 24, 2017, Steven Lo (Chief Commercial Officer) sold 2,290 shares at 33.24 per share price.On Jan 24, 2017, Charles R Eyler (officer ) sold 820 shares at 33.24 per share price.On Jan 24, 2017, Richard Paul Bryce (SR VP, CLINICAL RESEARCH & DEV) sold 2,293 shares at 33.24 per share price.
Puma Biotechnology Inc (NYSE:PBYI) witnessed a decline in the market cap on Wednesday as its shares dropped 10.56% or 4.05 points. After the session commenced at $38.05, the stock reached the higher end at $38.5 while it hit a low of $34.25. With the volume soaring to 904,794 shares, the last trade was called at $34.3. The company has a 52-week high of $73.27. The company has a market cap of $1,263 million and there are 36,818,092 shares in outstanding. The 52-week low of the share price is $19.74.
Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive metastatic breast cancer and gastric cancer and PB272 (neratinib intravenous) for the treatment of patients with advanced cancer. Puma Biotechnology, Inc. is headquartered in Los Angeles, California.